As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across ...

Representative Robert Bresnahan Jr. recently waved goodbye to his Regeneron Pharmaceuticals shares, sparking curiosity over ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Real-time index price for TSX Composite High Dividend Index (TXEI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% ...

Humankind Investments increased its stake in Regeneron Pharmaceuticals by 62.3%, showing rising investor interest despite the ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Regeneron Pharmaceuticals Up Nearly 7%, On Pace For Largest Percent Increase Since September 2022 — Data Talk Regeneron Pharmaceuticals, Inc. (REGN) is currently at $568.11, up $40.33 or 7.64% --On ...

The post shared by Ark’s multiomics analyst, Nemo M Despot, underscored that “AI is powering a self-reinforcing loop that ...

In a longer-term context, Regeneron's total shareholder return, including dividends, was a decline of 8.37% over the past five years. This performance trails the past year's market return of 8% and ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...